Inmune Beneish M Score

INMB
 Stock
  

USD 9.34  0.04  0.43%   

This module uses fundamental data of Inmune Bio to approximate the value of its Beneish M Score. Inmune Bio M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Inmune Bio Piotroski F Score and Inmune Bio Altman Z Score analysis.
  
The current year Total Debt is expected to grow to about 16.4 M. The current year Debt Current is expected to grow to about 86.8 K. Inmune Bio Total Assets Per Share are projected to slightly grow based on the last few years of reporting. The past year's Total Assets Per Share were at 5.60. The current year Net Current Assets as percentage of Total Assets is expected to grow to 84.47, whereas Cash Flow Per Share is forecasted to decline to (1.64) .
At this time, it appears that Inmune Bio is an unlikely manipulator. The earnings manipulation may begin if Inmune Bio's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Inmune Bio executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Inmune Bio's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.98
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables1.23Focus
Asset QualityN/AFocus
Expense Coverage1.04Focus
Gross Margin Strengs0.99Focus
Accruals Factor1.04Focus
Depreciation ResistanceN/AFocus
Net Sales Growth0.83Focus
Financial Leverage Condition1.0Focus

Inmune Bio Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Inmune Bio's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues150.8 K181 K
Fairly Down
Increasing
Slightly volatile
Selling General and Administrative Expense7.6 M8.8 M
Fairly Down
Increasing
Slightly volatile
Total Assets107.8 M99.9 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net589.3 K726 K
Significantly Down
Increasing
Slightly volatile
Trade and Non Trade Receivables16.6 K16.2 K
Fairly Up
Decreasing
Slightly volatile
Total Liabilities21.3 M19.7 M
Significantly Up
Increasing
Slightly volatile
Current Assets89.1 M82.6 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current18.8 M17.3 M
Significantly Up
Increasing
Slightly volatile
Current Liabilities4.7 M4.4 M
Significantly Up
Increasing
Slightly volatile
Liabilities Non Current16.6 M15.4 M
Significantly Up
Increasing
Slightly volatile
Total Debt16.4 M15.2 M
Significantly Up
Increasing
Slightly volatile
Debt Current86.8 K72 K
Fairly Up
Decreasing
Slightly volatile
Debt Non Current16.4 M15.2 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Inmune Bio Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Inmune Bio's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Inmune Bio in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Inmune Bio's degree of accounting gimmicks and manipulations.

About Inmune Bio Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(31.14 Million)

Inmune Bio Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease significantly based on the last few years of reporting. The past year's Earnings Before Interest Taxes and Depreciation Amortization EBITDA were at (30.34 Million)

About Inmune Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inmune Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inmune Bio Piotroski F Score and Inmune Bio Altman Z Score analysis. Note that the Inmune Bio information on this page should be used as a complementary analysis to other Inmune Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Inmune Stock analysis

When running Inmune Bio price analysis, check to measure Inmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inmune Bio is operating at the current time. Most of Inmune Bio's value examination focuses on studying past and present price action to predict the probability of Inmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inmune Bio's price. Additionally, you may evaluate how the addition of Inmune Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Inmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inmune Bio. If investors know Inmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
182.3 M
Quarterly Revenue Growth YOY
39.75
Return On Assets
-0.26
Return On Equity
-0.58
The market value of Inmune Bio is measured differently than its book value, which is the value of Inmune that is recorded on the company's balance sheet. Investors also form their own opinion of Inmune Bio's value that differs from its market value or its book value, called intrinsic value, which is Inmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inmune Bio's market value can be influenced by many factors that don't directly affect Inmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Inmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.